Blockage corrections for three-dimensional-flow closed-throat wind tunnels, with consideration of the effect of compressibility

Theoretical blockage corrections are presented for a body of revolution and for a three-dimensional unswept wing in a circular or rectangular wind tunnel. The theory takes account of the effects of the wake and of the compressibility of the fluid, and is based on the assumption that the dimensions of the model are small in comparison with those of the tunnel throat. Formulas are given for correcting a number of the quantities, such as dynamic pressure and Mach number, measured in wing-tunnel tests. The report presents a summary and unification of the existing literature on the subject

Blockage corrections for three-dimensional-flow closed-throat wind tunnels, with consideration of the effect of compressibility

Theoretical blockage corrections are presented for a body of revolution and for a three-dimensional unswept wing in a circular or rectangular wind tunnel. The theory takes account of the effects of the wake and of the compressibility of the fluid, and is based on the assumption that the dimensions of the model are small in comparison with those of the tunnel throat. Formulas are given for correcting a number of the quantities, such as dynamic pressure and Mach number, measured in wind-tunnel tests. The report presents a summary and unification of the existing literature on the subject

British Lung Foundation/United Kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders

A proportion of people living with common variable immunodeficiency disorders develop granulomatous-lymphocytic interstitial lung disease (GLILD). We aimed to develop a consensus statement on the definition, diagnosis, and management of GLILD. All UK specialist centers were contacted and relevant physicians were invited to take part in a 3-round online Delphi process. Responses were graded as Strongly Agree, Tend to Agree, Neither Agree nor Disagree, Tend to Disagree, and Strongly Disagree, scored +1, +0.5, 0, −0.5, and −1, respectively. Agreement was defined as greater than or equal to 80% consensus. Scores are reported as mean ± SD. There was 100% agreement (score, 0.92 ± 0.19) for the following definition: “GLILD is a distinct clinico-radio-pathological ILD occurring in patients with [common variable immunodeficiency disorders], associated with a lymphocytic infiltrate and/or granuloma in the lung, and in whom other conditions have been considered and where possible excluded.” There was consensus that the workup of suspected GLILD requires chest computed tomography (CT) (0.98 ± 0.01), lung function tests (eg, gas transfer, 0.94 ± 0.17), bronchoscopy to exclude infection (0.63 ± 0.50), and lung biopsy (0.58 ± 0.40). There was no consensus on whether expectant management following optimization of immunoglobulin therapy was acceptable: 67% agreed, 25% disagreed, score 0.38 ± 0.59; 90% agreed that when treatment was required, first-line treatment should be with corticosteroids alone (score, 0.55 ± 0.51)

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement

<div><p>Secondary antibody deficiency can occur as a result of haematological malignancies or certain medications, but not much is known about the clinical and immunological features of this group of patients as a whole. Here we describe a cohort of 167 patients with primary or secondary antibody deficiencies on immunoglobulin (Ig)-replacement treatment. The demographics, causes of immunodeficiency, diagnostic delay, clinical and laboratory features, and infection frequency were analysed retrospectively. Chemotherapy for B cell lymphoma and the use of Rituximab, corticosteroids or immunosuppressive medications were the most common causes of secondary antibody deficiency in this cohort. There was no difference in diagnostic delay or bronchiectasis between primary and secondary antibody deficiency patients, and both groups experienced disorders associated with immune dysregulation. Secondary antibody deficiency patients had similar baseline levels of serum IgG, but higher IgM and IgA, and a higher frequency of switched memory B cells than primary antibody deficiency patients. Serious and non-serious infections before and after Ig-replacement were also compared in both groups. Although secondary antibody deficiency patients had more serious infections before initiation of Ig-replacement, treatment resulted in a significant reduction of serious and non-serious infections in both primary and secondary antibody deficiency patients. Patients with secondary antibody deficiency experience similar delays in diagnosis as primary antibody deficiency patients and can also benefit from immunoglobulin-replacement treatment.</p></div

Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort

NACA Technical Reports

"Theoretical blockage corrections are presented for a body of revolution and for a three-dimensional, unswept wing in a circular or rectangular wind tunnel. The theory takes account of the effects of the wake and of the compressibility of the fluid, and is based on the assumption that the dimensions of the model are small in comparison with those of the tunnel throat. Formulas are given for correcting a number of the quantities, such as dynamic pressure and Mach number, measured in wind tunnel tests" (p. 771)

NACA Technical Reports

"Theoretical blockage corrections are presented for a body of revolution and for a three-dimensional unswept wing in a circular or rectangular wind tunnel. The theory takes account of the effects of the wake and of the compressibility of the fluid, and is based on the assumption that the dimensions of the model are small in comparison with those of the tunnel throat. Formulas are given for correcting a number of the quantities, such as dynamic pressure and Mach number, measured in wing-tunnel tests. The report presents a summary and unification of the existing literature on the subject" (p. 771)

NACA Research Memorandums

Memorandum discussing four related methods for the study of compressible flow by means of the linear perturbation theory for the case of three-dimensional flow with axial symmetry. A general method which includes the other is also discussed briefly. In each case, the properties of the compressible flow are obtained from those of a corresponding incompressible flow